JEITO

We are very pleased to share that our portfolio company Noema Pharma announced the completion of enrollment in the GALENE Phase 2B trial evaluating the efficacy of NOE-101 for seizure control in Tuberous Sclerosis Complex (TSC)! 👏 TSC is a debilitating disease characterized by serious, life-threatening seizures with long-term impact on brain development and caused by mutations in the TSC1 and TSC2 genes. Approximately 80,000 people in the US and EU are diagnosed with TSC, and about 60 percent of patients do not respond to current treatment options. Congratulations to the Noema Pharma team for this new achievement! Read more 👉 https://lnkd.in/e-eCrMbm #FasterForThePatient #Innovation #Biopharma #RareDisease #NeuromuscularDisease

🚀 We are very pleased to share that our portfolio company Advesya has received approval from the European Medicines Agency (EMA) to initiate the phase 1/2 trial of its lead asset, CCTx-001, to address the medical needs of patients with acute myeloid leukemia (AML).   AML is a cancer of the bone marrow and the blood that progresses rapidly without treatment   The #RESOLVE AML 001 study will determine the recommended phase 2 dose of CCTx-001 and will assess safety, tolerability, and clinical activity in patients with relapsed/refractory AML.   #biopharma #innovation #hematology #oncology #clinicalstudy

We are thrilled to announce JEITO's participation in the $150 million Series D financing of our portfolio company CatalYm GmbH, a clinical-stage biopharma developing novel immunotherapies to fight cancer. Jeito's new investment, alongside international biopharma investors, underscores Catalym’s strong progress and potential to treat patients suffering from the disease. These new funds will support the expansion of the clinical development plan for visugromab, Catalym’s monoclonal antibody designed to neutralize the GDF-15 protein produced by tumors, to confirm this lead asset as a new class of cancer immunotherapy. Remember, the story between CatalYm GmbH and JEITO started in November 2022 after a first investment as co-lead investor of a €50 million Series C financing. This new investment perfectly illustrates Jeito’s refinancing strategy aiming at continuously supporting portfolio companies with both a significant deployment of capital released upon milestones and a wide range of expertise provided by its collective team. Congratulations CatalYm GmbH! 👏 Read more 👉 https://lnkd.in/eRfKBPZi #FasterForThePatient #privateequity #investment #lifesciences #biopharma #immunotherapy #innovation

They are the new faces of the NMD Pharma A/S management team ⤵️ Our portfolio company, developing novel and improved treatments for patients living with rare and severe neuromuscular diseases, is bolstering its executive team with three new senior recruits to support NMD Pharma A/S's strong development. ➡ Peter Kasten will join NMD Pharma as VP Finance ➡ Cecilia Sparr Eskilsson as VP Project Management ➡ Maja Nielsen as HR Director of People As NMD Pharma will have launched three Phase 2 trials by the end of the year, their strong experience and talent will play a crucial role in the company's continued success. We wish them a fruitful collaboration! #JeitoPortfolio #leadership #appointment #biopharma #neuromusculardisease https://lnkd.in/gQgrfRiK

A few weeks after the official signing, Jeito Capital is delighted to share the successful closing of its portfolio company EyeBio by Merck & Co (MSD) for up to $3 billion. This exit comes as the EyeBio team, led by David Guyer, co-founder & CEO, with its co-founder & CSO Tony Adamis, has made tremendous progress over the past two years with Restoret™, EyeBio's promising late-stage candidate for diabetic macular edema. A new hope dawns for patients with sight-threatening eye conditions. Congratulations to all the stakeholders involved in this achievement. 👏 #FasterForThePatient #privateequity #lifesciences #biopharma #ophthalmology

For France Biotech's "Investor Views" broadcast, Sabine Dandiguian, Managing Partner, highlighted JEITO's strategy and its fit with the current M&A dynamic as illustrated through Jeito Capital's two recent successful exits.   "𝘛𝘰 𝘢𝘯𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘦 𝘵𝘩𝘦 𝘱𝘢𝘵𝘦𝘯𝘵 𝘤𝘭𝘪𝘧𝘧, 𝘉𝘪𝘨 𝘗𝘩𝘢𝘳𝘮𝘢 𝘤𝘢𝘯 𝘳𝘦𝘭𝘺 𝘰𝘯 𝘵𝘩𝘦𝘪𝘳 𝘪𝘯𝘵𝘦𝘳𝘯𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩, 𝘣𝘶𝘵 𝘯𝘰𝘵 𝘦𝘹𝘤𝘭𝘶𝘴𝘪𝘷𝘦𝘭𝘺. 𝘛𝘩𝘦𝘺 𝘢𝘳𝘦 𝘰𝘯 𝘵𝘩𝘦 𝘭𝘰𝘰𝘬𝘰𝘶𝘵 𝘧𝘰𝘳 𝘴𝘵𝘢𝘳𝘵𝘶𝘱 𝘢𝘤𝘲𝘶𝘪𝘴𝘪𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘧𝘪𝘭𝘭 𝘵𝘩𝘪𝘴 𝘦𝘯𝘰𝘳𝘮𝘰𝘶𝘴 𝘷𝘰𝘪𝘥. 𝘑𝘦𝘪𝘵𝘰 𝘪𝘴 𝘱𝘦𝘳𝘧𝘦𝘤𝘵𝘭𝘺 𝘱𝘰𝘴𝘪𝘵𝘪𝘰𝘯𝘦𝘥 𝘵𝘰 𝘴𝘦𝘪𝘻𝘦 𝘵𝘩𝘪𝘴 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘺."   Watch the full video here 👉 https://lnkd.in/gCCiKxnv   #privateequity #finance #innovation #lifescience #pharma #biopharma

At « Les Rencontres d'Aix » , our Founder and CEO Rafaèle Tordjman shared her views with Yasmine Belkaid, Nicolas Dubourg, Norah Patten on the balance between public and private fundings to accelerate innovation. As a private investor, Rafaèle Tordjman had the opportunity to: ➡️ Reaffirm how complementary these financings are ➡️ Put emphasis on the importance of having both experienced team and funds to finance in continuity and convert patents coming from R&D into future and concrete innovative drugs ➡️ Share her vision on new ways to foster innovation among which the intensification of public-private partnerships, the use of AI, the direct investment of universities in funds to benefit from their returns that can be reinvested in R&D, and the role of philanthropy. Ariel Mendez Philippe Escande Institut de la Vision Institut Imagine EFS Sanofi Servier Paris Saclay Cancer Cluster (PSCC) Gustave Roussy Institut Pasteur Novo Nordisk Foundation Dassault Systèmes European Investment Fund (EIF) Bpifrance Groupe Caisse des Dépôts. At Jeito, we embrace these ambitions to accelerate innovation to bring benefits to the patients.   Watch the replay 👉 https://lnkd.in/eG9Atj3z #ReAix #finance #privateequity #innovation #health #biopharma

"Privatizing Research to Share Innovation?": Don't miss this exceptional conference at the Rencontres Économiques d'Aix-en-Provence featuring Rafaèle Tordjman, Founder and CEO of JEITO.   Alongside Yasmine Belkaid (Institut Pasteur), Nicolas Dubourg (ISALT), Norah Patten, Bioastronautics Researcher, Rafaèle Tordjman will share her vision on how private and public sectors can collaborate to drive tomorrow's health innovations efficiently.   Follow online the engaging discussions moderated by Philippe Escande (Le Monde) 👉 https://lnkd.in/eQUjehP6   📍Saturday, July 6th, at 5 PM!   #ReAix #innovation #recherche #santé

Few weeks after the official signing, Jeito Capital is pleased to announce the closing of the acquisition of its portfolio company Hi-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion.   Building on the significant progress achieved, HI-Bio™ is in a strong position to accelerate its late-stage clinical development programs for felzartamab, its lead clinical therapeutic candidate in the treatment of severe immune-mediated diseases. With Biogen, a leading global biotechnology company, HI-Bio™ is beginning a new phase of growth aimed at bringing innovative therapies to patients with high unmet needs. Congratulations to the whole HI-Bio: A Biogen Company™ teams! #FasterForThePatient #privateequity #lifesciences #biopharma #exit #mmunology

What does it mean to be a visionary leader in healthcare innovation?   Inspiring theme to kick off the very first edition of the HealthTech Accelerations Summit in Lyon organized by Biotech Finances !   Jeito's Managing Partner, Sabine Dandiguian, took the stage to share her insights alongside Alain Huriez, Denis Lucquin, Thierry Mauvernay, Frédéric Girard, and Jacques-Bernard Taste.   A visionary is a leader who combines both patient-focused and economic visions. "𝘛𝘩𝘦 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘣𝘦𝘯𝘦𝘧𝘪𝘵 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘥 𝘵𝘰 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘴 𝘢 𝘧𝘶𝘯𝘥𝘢𝘮𝘦𝘯𝘵𝘢𝘭 𝘦𝘭𝘦𝘮𝘦𝘯𝘵 𝘰𝘧 𝘴𝘶𝘤𝘤𝘦𝘴𝘴”, emphasized Sabine Dandiguian   “𝘍𝘶𝘳𝘵𝘩𝘦𝘳𝘮𝘰𝘳𝘦, 𝘢 𝘷𝘪𝘴𝘪𝘰𝘯𝘢𝘳𝘺 𝘤𝘢𝘯𝘯𝘰𝘵 𝘴𝘶𝘤𝘤𝘦𝘦𝘥 𝘢𝘭𝘰𝘯𝘦. 𝘝𝘪𝘴𝘪𝘰𝘯𝘢𝘳𝘪𝘦𝘴 𝘮𝘢𝘬𝘦 𝘢 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘵𝘩𝘦𝘪𝘳 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘣𝘶𝘪𝘭𝘥 𝘢 𝘶𝘯𝘪𝘲𝘶𝘦 𝘵𝘦𝘢𝘮 𝘰𝘧 𝘥𝘪𝘷𝘦𝘳𝘴𝘦 𝘪𝘯𝘥𝘪𝘷𝘪𝘥𝘶𝘢𝘭𝘴 𝘸𝘩𝘰 𝘴𝘦𝘦 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵𝘭𝘺 𝘢𝘯𝘥 𝘤𝘢𝘯 𝘱𝘪𝘤𝘬 𝘶𝘱 𝘰𝘯 𝘴𝘪𝘨𝘯𝘢𝘭𝘴 𝘵𝘩𝘢𝘵 𝘰𝘵𝘩𝘦𝘳𝘴 𝘮𝘪𝘨𝘩𝘵 𝘮𝘪𝘴𝘴. 𝘈𝘵 𝘑𝘦𝘪𝘵𝘰, 𝘰𝘶𝘳 𝘤𝘰𝘭𝘭𝘦𝘤𝘵𝘪𝘷𝘦 𝘢𝘱𝘱𝘳𝘰𝘢𝘤𝘩 𝘪𝘴 𝘢 𝘬𝘦𝘺 𝘴𝘵𝘳𝘦𝘯𝘨𝘵𝘩 𝘵𝘩𝘢𝘵 𝘸𝘦 𝘱𝘢𝘺 𝘢𝘵𝘵𝘦𝘯𝘵𝘪𝘰𝘯 𝘵𝘰 𝘢𝘭𝘴𝘰 𝘪𝘯 𝘵𝘩𝘦 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴 𝘸𝘦 𝘪𝘯𝘷𝘦𝘴𝘵 𝘪𝘯", she added   🙏 BiotechFinances - Medtech - Santé Numérique - DTx - Intelligence Artificielle - Medtech - Santé Numérique - DTx - Intelligence Artificielle   #HealthTechAccelerationsSummit #leadership #innovation #healthcare #biopharma